{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:50:24Z","timestamp":1773939024905,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vhri.2024.101035","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T18:38:22Z","timestamp":1724783902000},"page":"101035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient and Caregiver Preferences for Hemophilia A Treatment in Taiwan: A Discrete Choice Experiment"],"prefix":"10.1016","volume":"45","author":[{"given":"Shyh-Shin","family":"Chiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te-Fu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaan-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2024.101035_bib1","first-page":"7","article-title":"Hemophilia A: strategies for improving long-term holistic management, adherence, and quality of life","volume":"13","author":"Escobar","year":"2022","journal-title":"J\u00a0Adv Pract Oncol"},{"issue":"4","key":"10.1016\/j.vhri.2024.101035_bib2","first-page":"CD010422","article-title":"Gene therapy for haemophilia","volume":"4","author":"Sharma","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 5","key":"10.1016\/j.vhri.2024.101035_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/hae.14037","article-title":"Treatment preferences in people with haemophilia A or caregivers of people with haemophilia A: a discrete choice experiment","volume":"26","author":"Fifer","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13023-019-1175-5","article-title":"Haemophilia A: health and economic burden of a rare disease in Portugal","volume":"14","author":"Caf\u00e9","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13023-022-02300-1","article-title":"Differential humanistic and economic burden of mild, moderate and severe haemophilia in European adults: a regression analysis of the CHESS II study","volume":"17","author":"Rodriguez-Santana","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.vhri.2024.101035_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jfma.2021.07.017","article-title":"Evolution of congenital haemophilia care in Taiwan","volume":"121","author":"Chen","year":"2022","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"8","key":"10.1016\/j.vhri.2024.101035_bib7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.vhri.2024.101035_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810228","article-title":"The arrival of gene therapy for patients with hemophilia A","volume":"23","author":"Castaman","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.vhri.2024.101035_bib10","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.vhri.2024.101035_bib11","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in hemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.vhri.2024.101035_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.vhri.2024.101035_bib13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.12178","article-title":"Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study","volume":"19","author":"Gringeri","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib14","first-page":"35","article-title":"Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study","volume":"114","author":"Tagliaferri","year":"2015","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.vhri.2024.101035_bib15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2516.2009.02077.x","article-title":"Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.vhri.2024.101035_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17474086.2018.1486704","article-title":"Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"Suppl 6","key":"10.1016\/j.vhri.2024.101035_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.vhri.2024.101035_bib19","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"21","key":"10.1016\/j.vhri.2024.101035_bib20","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Blood Spotlight Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.vhri.2024.101035_bib22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"04","key":"10.1016\/j.vhri.2024.101035_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib24","first-page":"73","article-title":"Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era","volume":"19","author":"Pasca","year":"2021","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/hae.12011","article-title":"Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII","volume":"19","author":"Gelhorn","year":"2013","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.vhri.2024.101035_bib28","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1111\/hae.14137","article-title":"Patient and caregiver preferences for haemophilia A treatments: a discrete choice experiment","volume":"26","author":"Su","year":"2020","journal-title":"Haemophilia"},{"issue":"17","key":"10.1016\/j.vhri.2024.101035_bib29","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.vhri.2024.101035_bib30","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/PPA.S254934","article-title":"Oncologist and patient preferences for attributes of CDK4\/6 inhibitor regimens for the treatment of advanced\/metastatic HR positive\/HER2 negative breast cancer: discrete choice experiment and best\u2013worst scaling","volume":"14","author":"Maculaitis","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.vhri.2024.101035_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.14383","article-title":"Patient preferences and priorities for haemophilia gene therapy in the US: a discrete choice experiment","volume":"27","author":"Witkop","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.vhri.2024.101035_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"Hacker","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.vhri.2024.101035_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/PPA.S151812","article-title":"Patient preferences in the treatment of hemophilia a: impact of storage conditions on product choice","volume":"12","author":"Tischer","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.vhri.2024.101035_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3349\/ymj.2013.54.1.71","article-title":"Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan","volume":"54","author":"Tu","year":"2013","journal-title":"Yonsei Med J"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:21:12Z","timestamp":1739233272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"alternative-id":["S2212109924000682"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101035","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient and Caregiver Preferences for Hemophilia A Treatment in Taiwan: A Discrete Choice Experiment","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101035"}}